BGI Research

A team of researchers has reported for the first time the live birth of a monkey that contains a high proportion of cells derived from a monkey stem cell line. This 'chimeric' monkey is composed of cells that originate from two genetically distinct embryos of the same species of monkey. This has previously been demonstrated in rats and mice but, until now, has not been possible in other species, including non-human primates. A team of researchers in China has reported for the first time the live birth of a monkey that contains a high proportion of cells derived from a monkey stem cell line. This "chimeric" monkey is composed of cells that originate from two genetically distinct embryos of the same species of monkey. This has previously been demonstrated in rats and mice but, until now, has not been possible in other species, including non-human primates. The details of the research are reported November 9 in the journal Cell. "This is a long-sought goal in the field," says senior author Zhen Liu of the Chinese Academy of Sciences (CAS). "This research not only has implications for understanding naive pluripotency in other primates, including humans, but it also has relevant practical implications for genetic engineering and species conservation. Specifically, this work could help us to generate more precise monkey models for studying neurological diseases as well as for other biomedicine studies." The monkeys used in the study were cynomolgus monkeys, also known as crab-eating or long-tailed macaques, a primate common in biomedical research. The investigators first established nine stem cell lines using cells removed from 7-day-old blastocyst embryos. They then placed the cell lines in culture to give them enhanced ability to differentiate into different cell types. They performed a number of different tests on the cells to confirm that they were pluripotent -- having the ability to differentiate into all of the cell types needed to create a live animal. The stem cells were also labeled with green fluorescent protein so the researchers would be able to determine which tissues had grown out of the stem cells in any animals that developed and survived. Ultimately, they selected a particular subset of stem cells to inject into early monkey morula embryos (embryos that are 4-5 days old). The embryos were implanted into female macaques, resulting in 12 pregnancies and six live births. Analysis confirmed that one monkey that was born alive and one fetus that was miscarried were substantially chimeric, containing cells that grew out of the stem cells throughout their bodies. Both were male. The investigators used the green fluorescent protein label to determine which tissues contained cells derived from the injected stem cells. They also used gene sequencing and other tests to confirm the presence of stem-cell-derived tissue across different organs. The tissue types they tested that contained the stem-cell-derived cells included the brain, heart, kidney, liver, and gastrointestinal tract. In the live monkey, the contribution of the stem cells in the different tissue types ranged from 21% to 92%, with an average of 67% across the 26 different types of tissue that were tested. The numbers were lower in the monkey fetus. In both animals, they also confirmed the presence of stem-cell-derived cells in the testes and in cells that eventually develop into sperm cells. "In this study, we have provided strong evidence that naive monkey pluripotent stem cells possess the capability of differentiating in vivo into all the various tissues composing a monkey body," says co-corresponding author Miguel Esteban of BGI Research and CAS. "This study deepens our understanding of the developmental potential of pluripotent stem cells in primate species." "This work helps us to better understand naive pluripotency in primate cells," adds co-corresponding author Qiang Sun of CAS. "In the future, we will try to increase the efficiency of this method for generating chimeric monkeys by optimizing the culture conditions for the stem cells, the cultures for the blastocysts where the stem cells are inserted, or both." The investigators also plan to further explore the mechanisms that underlie the survival of the embryos in the host animals, which they say will help improve the efficiency of chimera generation. This work was funded by the National Key Research and Development Program of China, the National Natural Science Foundation of China, the Shanghai Municipal Science and Technology Major Project, the Strategic Priority Research Program of the Chinese Academy of Sciences, the Basic Frontier Scientific Research Program of Chinese Academy of Sciences, the National Science and Technology Innovation 2030 Major Program, and Shenzhen Basic Research Project for Excellent Young Scholars.

DUBLIN, Sept. 11, 2023 /PRNewswire/ -- The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. In the ever-evolving landscape of the diagnostic industry, immunoassay is emerging as a steadfast workhorse, finding new relevance driven by the demands of the ongoing pandemic. The need for rapid, easily accessible diagnostics has propelled immunoassay to the forefront, as it adapts and advances in response to shifting market dynamics. Advancements in genetic knowledge are opening up new avenues for immunoassay technologies, with multiplex capabilities becoming the standard. This transformation extends to rapid diagnostics, point-of-care solutions, biomarker exploration, and the expanding consumer market, while traditional immunoassay methods continue to hold a strong position within the growing realm of clinical diagnostics. Within the realm of immunoassay instrumentation, multiple factors are fueling growth, including ongoing diagnostic breakthroughs, the retirement of older instruments driven by evolving technologies, wider consumer adoption, and the maturation of immunity-related technology. However, these opportunities are not without their challenges. Heightened competition is exerting downward pressure on prices, while the threat from PCR-based instruments looms. Lower barriers to entry and potential drawbacks associated with wellness trends also present limitations to growth. This dynamic landscape is characterized by enduring instruments, industry structures in flux due to declining instrument costs, and meticulous instrument specifications, which play a pivotal role in shaping the field. Innovations like CRISPR diagnostics further contribute to the evolving immunoassay landscape. With profiles of over 60 companies, spanning both large and small players in this field, this comprehensive report offers invaluable insights into the pitfalls and opportunities that define the immunoassay industry. It equips stakeholders to make informed investment decisions and valuations, providing the latest data to navigate this ever-changing landscape with confidence. Key Topics Covered: Industry Overview Players in a Dynamic Market Academic Research Lab Diagnostic Test Developer Instrumentation Supplier Chemical/Reagent Supplier Pathology Supplier Independent Clinical Laboratory Public National/regional Laboratory Hospital Laboratory Physicians Office Lab (POLS) Audit Body Certification Body The Clinical Laboratory Market Segments Traditional Market Segmentation Laboratory Focus and Segmentation Hospital Testing Share Economies of Scale Hospital vs. Central Lab Physician Office Lab's Physician's and POCT Immunoassay - Markets and Discussion Instruments - Genetics changes the picture RIA - A Technology Shows its Age Immunoassay vs. PCR vs. Sequencing - A See Saw Battle The Smart Shrinking Instrument - Serious Implications Research Funding and Capital Expense - Instrument Pooling Multiplex vs. POC - A Tradeoff Analysis Reagents and Kits - Genetics changes the picture Bigger Test Menus a Boon for Kit Market Physician Office Labs - A New Frontier Rapid and POCT to Threaten Instrument Markets OTC and DTC - Huge Market Potential Economies of Scale. Going Away? Lower Barriers to Entry for Instruments/Analyzers Miniturization and Technology Drive Acquisition Immunoassay Recent Developments Recent Developments - Importance and How to Use This Section EDP Biotech, New Day Diagnostics to Merge Sorrento Therapeutics Nabs Contract for Dx Platform Beckman Coulter Diagnostics DxI 9000 Access Immunoassay Analyzer Qorvo Eyes Multiplex Immunoassay BioMerieux Launches New Products Senzo to Commercialize Infectious Disease Lateral Flow Tests Nanomix Plans Instrument, Test Launches Startup GLX Analytix Prepares for Commercialization Nonagen Gets CE Mark for Bladder Cancer Immunoassay Qualigen Acquires Majority Stake in NanoSynex Saladax Biomedical Using Immunoassay Dx Prolight Diagnostics to Acquire Psyros Diagnostics Quidel to Acquire Ortho Clinical Diagnostics FDA Grants EUA to Xtrava Health Alamar Biosciences Develops Immuno-Sandwich Platform FDA grants breakthrough device to multiplex immunoassay Quidel, Beckman Settle Cardiac Immunoassay Dispute BGI Americas, Advaite Form SARS-CoV-2 Testing Partnership BioMerieux Gets CE Mark for Three Dengue Immunoassays COVID-19 Portfolio to Accelerate At-Home Infectious Disease Testing Roche Diagnostics Expanding Testing Portfolio in 2021 PerkinElmer Long-Term Outlook Quidel Updates Outlook for C19 Testing Dx Companies Look at Multiplex Tests for SARS-CoV-2, Influenza Becton Dickinson and NAT Diagnostics Acquisition Market Trends Factors Driving Growth Diagnostic Factors Changing Technologies Spur Early Instrument Retirement Consumer Channels Open Wider Immunity Technology Comes of Age Factors Limiting Growth Increased Competition Lowers Price Threat from PCR Based Instruments Lower Barriers to Entry Wellness has a downside Immunoassay Instrumentation Instrumentation Tenacity Declining Cost of Instruments Changes Industry Structure LISTING of INSTRUMENT SPECIFICATIONS Immunoassay - CRISPR Diagnostics Market Guides Immunoassay Market - Strategic Situation Analysis Guide for Executives, Marketing, Sales and Business Development Staff Guide for Management Consultants and Investment Advisors Market Definition Immunoassay Markets Definition In This Report Enzyme Based Immunofluorescence Chemiluminescence DNA/NAT RIA & Other Reagents/Kits, Analyzers, Software & Services Infectious Disease Auto Immune Endocrinology Oncology Cardiology Other Specialty Market Definition Methodology Perspective: Healthcare and the IVD Industry Global Healthcare Spending Spending on Diagnostics Important Role of Insurance for Diagnostics Appendices United States Medicare System: Laboratory Fees Schedule The Most Used IVD Assays The Highest Grossing Assays Profiles of Key Companies Abbott Laboratories Abcam Abionic Accel Diagnostics Applied BioCode Arlington Scientific Arrayit Corporation Atomo Diagnostics Aureum Diagnostics Aurora Biomed Autobio Diagnostics AVIVA Systems Biology Awareness Technology Axis-Shield Diagnostics Ltd. Beckman Coulter Diagnostics Becton, Dickinson and Company Biocartis Biomatik bioMerieux Diagnostics Bioneer Corporation Bio-Rad Laboratories, Inc. BioTek Instruments Boditech Med, Inc Boster Biological Technology Diamedix (Erba Diagnostics) Diasorin S.p.A. Dynex Technologies Enzo Biochem Eurofins Scientific FUJIFILM Wako Diagnostics Fujirebio Gold Standard Diagnostics Grifols Hycor Biomedical Immunodiagnostic Systems (IDS) Immunodiagnostik AG Inova Diagnostics JR Biomedical Luminex Corp Maxim Biomedical Mbio Diagnostics Meso Scale Discovery Millipore Sigma Mindray Molecular Devices MP Biomedical Operon Ortho Clinical Diagnostics Perkin Elmer Qiagen Quidel R&D Systems Randox Toxicology Roche Molecular Diagnostics SD Biosensor Siemens Healthineers Sysmex Tecan Thermo Fisher Scientific Inc. TOSOH Bioscience Veredus Laboratories Vircell YD Diagnostics Zhejiang Orient Gene Biotech Scope of the Report Global Market by Application Endocrinology Applications Immune Applications Oncology Applications Infectious Disease Applications Cardiology Applications Other Applications Immunoassay by Technology Enzyme Flourescence Chemiluminescence Nucleic Acid Rapid/POC Other Technology Immunoassay by Product Instrument Reagents Services Immunoassay by User Hospital Outpatient Lab POC/Other 12 Vision of the Future of Immunoassay For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

HACKENSACK, NJ / ACCESSWIRE / August 22, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, kicks-off its annual series of events by hosting a scientific symposium at the Museum of Science, in Boston, Massachusetts on September 26th. This year's event, titled "Uncovering Integrative Approaches for Oncology Drug Development" will focus on how the integrated use of clinically relevant patient-derived models, multi-omics analytics, and high complexity phenotypical assays are impacting the entire drug development continuum across multiple therapeutic modalities. With a remarkable lineup of nine speakers representing biopharma companies including AstraZeneca, Codagenix, Blueprint Medicines, Bicycle Therapeutics, C4 Therapeutics, and Corellia AI, talks will provide the latest insights about exciting preclinical and clinical programs and discuss the use of innovative integrated approaches to accelerate their oncology programs. The event will be opened by a distinguished keynote speaker, Dr. Olivier Elemento from Cornell Medicine, who will discuss advancements and the future of oncology precision medicine. Champions' Chief Executive Officer, Ronnie Morris said, "As a leading partner for both preclinical and clinical programs, Champions Oncology is proud to host an event that will bring together a renowned group of leaders in the field and enable enlightening and exciting scientific discussions, that will result in the achievement of our shared mission of improving patient's lives". The symposium will feature Champions' Senior Scientific Director, Dr. Stefano Cairo, and the Director of Flow Cytometry, Dr. Brandon Walling, presenting the latest advancement in integrative approaches using patient-derived models and high-complexity flow cytometry in translational research. The event is proudly sponsored by Champions in partnership with BGI Americas and Emulate and is free to attend, with limited seats. For the full agenda and to register for the upcoming symposium, visit our website at: About Champions Oncology Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit . Media Contact: Rachel Bunting, MS, MBA VP, Global Marketing Marketing@ChampionsOncology.com Website: Facebook: LinkedIn: Twitter: Instagram: SOURCE: Champions Oncology, Inc. View source version on accesswire.com: